Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

Today 15:30

RNS Number : 3876J
GSK PLC
23 June 2026
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Jonathan Symonds

b)

Position/status

Non-Executive Chair

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Purchase of 1,550 Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.3524

1,550

d)

Aggregated information

 

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2026-06-19

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth (Liz) McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 789 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

 

789

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,855 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

1,855

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 745 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

745

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 667 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

667

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 802 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

802

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Purchase of 1,266 ADS

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.6908

1,266

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-06-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEMSADEMSEEM
Date   Source Headline
23rd Jun 20257:00 amRNSTransaction in Own Shares
20th Jun 20257:00 amRNSArexvy filed in Japan for 18-49 at increased risk
20th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20253:30 pmRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSGSK submits Arexvy for adults 18+ with EMA
12th Jun 202511:00 amPRNDirector/PDMR Shareholding
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20253:30 pmRNSDirector/PDMR Shareholding
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSGSK - second tranche of share buyback programme
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20253:30 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:00 pmRNSTotal Voting Rights
2nd Jun 20257:00 amRNSLinerixibat file accepted for review by US FDA
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 202512:00 pmRNSGSK stops Phase 3 trial on cUTIs for efficacy
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 202512:16 pmRNSpositive CHMP opinion on Blenrep in EU
23rd May 20257:00 amRNSFDA approves Nucala COPD indication
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20253:30 pmRNSDirector/PDMR Shareholding
20th May 20257:00 amRNSTransaction in Own Shares
19th May 20257:00 amRNSBlenrep for 2L+ multiple myeloma approved in Japan
19th May 20257:00 amRNSTransaction in Own Shares
16th May 20257:00 amRNSTransaction in Own Shares
15th May 20257:00 amRNSTransaction in Own Shares
14th May 20257:00 amRNSGSK to acquire efimosfermin
14th May 20257:00 amRNSTransaction in Own Shares
13th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 202512:56 pmRNSUpdate on belrestotug development programme
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.